What the FDA Relabeling of Abacavir Means for You and Your Patient

If HSR Symptoms are Present⁴

November 2008

Now for patients who are about to receive abacavir, this is a suggested algorithm for approaching the prob. First one must determine is HLA-B*5701 testing is available. If it is not avail or if the clinician has no access to test, then provider should review risk factors with patient and start abacavir therapy and monitor for the occurrence of hypersensitivity reaction looking for signs and symptoms consistent with syndrome.

However, if testing is available, then the status of this allele should be determined with lab testing. If negative, the provider should proceed with initiating abacavir therapy. If the allele is present, then abacavir therapy should be avoided.

< Previous Slide

If HSR Symptoms are Present4

Next Slide >

 

Jump to section:

• Introduction
• Highly Active Antiretroviral Therapy
• Abacavir
• FDA Caution and Relabeling
• Abacavir Hypersensitivity
• Abacavir HSR and HLA Gene
• HLA-B Antigens and Alleles
• Naming Conventions - HLA-B*5701
• Chromosome 6
• Detecting HLA Alleles
• HLA-B*5701 Correlations
• HLA-B*5701 Correlations
• Clinical Utility³
• Problems
• If HSR Symptoms are Present⁴
• If HSR Symptoms are Present⁴
• Recommendations for Physicians⁵
• Recommendations for Physicians⁵
• Information for Patients⁵
• Information for Patients⁵
• HLA-B*5701 Genotyping
• References
• Questions?